# Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

> **NCT00622869** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 719 (actual)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** Tacrolimus (reduced tacrolimus)
- **DRUG:** Tacrolimus (tacrolimus elimination)
- **DRUG:** Tacrolimus (tacrolimus control)
- **DRUG:** Everolimus (reduced tacrolimus)
- **DRUG:** Everolimus (tacrolimus elimination)
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT00622869
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 719 (ACTUAL)
- **Last updated:** 2013-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622869, "Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00622869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*